Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsSandip Kapadia is recorded as CFO at Harmony Biosciences Holdings, Inc. (HRMY). The newest filing on record that lists Sandip Kapadia as CFO at Harmony Biosciences Holdings, Inc. (HRMY) is dated April 4, 2025. Harmony Biosciences Holdings, Inc. reported in an 8-K filed October 5, 2023 that Sandip Kapadia was appointed Chief Financial Officer and Chief Administrative Officer, effective September 30, 2023. The proxy statement of Harmony Biosciences Holdings, Inc. reports total compensation of $3,070,401 for Sandip Kapadia in fiscal 2024, including a base salary of $507,606. Disclosed compensation is on record for 6 fiscal years. Sandip Kapadia has spoken on 20 earnings calls across 1 company, most recently for Harmony Biosciences Holdings, Inc. on February 24, 2026. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member) and 7 others.
“The Board of Directors of Harmony Biosciences Holdings, Inc. (the "Company") appointed Sandip Kapadia, the Company's Chief Financial Officer, to the title of Chief Financial Officer and Chief Administrative Officer, effective upon Mr. Kapadia's acceptance on September 30, 2023.”
“This morning, we issued our fourth quarter earnings release and filed our 10K, where you'll find the details of our fourth quarter and full year 2025 financial and operating results.”
“This morning, we issued our third quarter 2025 earnings release and filed our 10-Q, where you'll find the details of our financial and operating results. We delivered strong financial results in the third quarter with our highest quarter-to-date in revenues and cash generation.”
“This morning, we issued our second quarter 2025 earnings release and filed our 10-Q with operating results. We had a great first half of the year. We delivered another quarter of solid financial performance with continued double-digit top line growth, sustained profitability, and robust cash generation.”
“This morning, we issued our first quarter 2025 earnings release and filed our 10-Q, where you’ll find the details of our financial and operating results. Our financial performance is also shown on Slides 12 through 14.”
“This morning, we issued our fourth quarter earnings release and filed our 10-K, where you will find the details of our fourth quarter and full year 2024 financial and operating results.”
Start not stated–present
Last confirmed April 4, 2025
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer and Chief Administrative Officer | $507,606 | $3,070,401 |
| 2023 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer and Chief Administrative Officer | $507,606 | $5,580,524 |
| 2022 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer and Chief Administrative Officer | $476,625 | $962,602 |
| 2021 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer and Chief Administrative Officer | $354,155 | $6,223,933 |
| 2020 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer | — | — |
| 2019 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Financial Officer | — | — |
